Full-Time

Senior Product Manager

Posted on 3/5/2026

Weave

Weave

11-50 employees

Generative AI platform for life-science collaboration

Compensation Overview

$175k - $200k/yr

+ Equity

San Francisco, CA, USA

Hybrid

Hybrid in SF Bay Area with in-office Tue/Wed/Thu and remote Mon/Fri.

Category
Product (1)
Required Skills
Product Management
Requirements
  • Minimum of 5 years of experience in product management within Business-to-Business Software as a Service companies.
  • Bachelor's degree in a related field.
  • Knowledge of drug discovery and development processes or advanced training in biology.
  • Proficiency in communicating complex information across various mediums including spoken, written, and visual formats.
  • Ability to communicate effectively with engineering, sales, executive, and stakeholder teams.
Responsibilities
  • Develop a deep understanding of customer and user needs, aspirations, and frustrations to create value for the organization.
  • Collaborate with the team to produce and document product plans that identify specific problems to solve and target audiences.
  • Ensure business sustainability by focusing on lean building practices and high-impact outcomes.
  • Maintain team focus on high-value tasks by filtering out distractions and surprises.
  • Ensure customers realize promised value by overseeing the completion of necessary tasks and project requirements.
Desired Qualifications
  • Advanced degree in a related field.
  • Experience building products for therapeutics or life science companies.

Weave.bio provides a platform for life sciences collaboration by integrating a generative AI system with a knowledge graph to connect researchers, data, and projects. The platform generates insights and maps connections across datasets, research teams, and workflows, while an incentive system rewards contributors proportionally to the value they add. Unlike tools that focus on a single function, Weave.bio combines collaboration features with a data-linking graph and an explicit rewards model to reduce silos and encourage sharing. The goal is to accelerate biomedical research and development, helping pharma, biotech, and academic researchers move from discovery toward real-world impact faster.

Company Size

11-50

Company Stage

Series A

Total Funding

$31.6M

Headquarters

New Haven, Connecticut

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • $20M Series A in October 2025 fuels global expansion and AI enhancements.
  • Strategic Advisory Board from Takeda and Gilead accelerates platform adoption.
  • Parexel partnership cuts NDA authoring time by over 60%.

What critics are saying

  • FDA's March 2026 guidance mandates human-only validation, blocking AutoIND features.
  • Rivanna Labs' May 2026 open-source RegAI Pro undercuts Weave's subscriptions.
  • EMA's July 2026 rules bar Weave from 35% of EU pipeline without on-premise deployment.

What makes Weave unique

  • Weave's AI-native platform automates full eCTD dossiers from IND to NDA authoring.
  • Built-in Data Room ensures traceability linking source data to submissions seamlessly.
  • Parexel-exclusive NDA templates leverage 40 years of regulatory expertise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

22%
Business Wire
Mar 25th, 2026
Weave Bio forms strategic advisory board to guide AI-driven regulatory science evolution

Weave Bio, an AI-driven regulatory automation company, has established its inaugural Strategic Advisory Board to guide the development of its platform and advance AI adoption in life sciences regulation. The board comprises senior executives from pharmaceutical companies and academia, including leaders from Takeda, Boehringer Ingelheim, Gilead, Stanford University and Serrado Capital. The SAB formation follows significant momentum for the San Francisco-based startup, which raised $20 million in Series A funding in October 2025 and announced a strategic partnership with Parexel. Weave Bio's platform streamlines regulatory content preparation for pharmaceutical companies, reducing regulatory timelines by over 50 percent whilst maintaining FDA and EMA compliance standards. Founded in 2022, Weave Bio has raised backing from investors including USVP, Innovation Endeavors and Magnetic Ventures.

Business Wire
Oct 18th, 2025
Weave Bio Secures $20M Series A Funding to Enhance Its AI-Native Regulatory Platform

Weave Bio raises $20M Series A to expand its AI-native platform that accelerates regulatory workflows for drug development.

FinSMEs
Oct 17th, 2025
Weave Bio Raises $20M in Series A Funding

Weave Bio raises $20M in Series A funding. Weave Bio, a San Francisco, CA-based provider of AI-native regulatory automation management solutions, raised $20m in Series A funding. The round, which brought total capital raised to $36m, was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. The company intends to use the funds to accelerate product development and expand its commercial team. In details, Weave Bio will: * complete its coverage of the entire regulatory lifecycle of therapeutics, inclusive of market applications (NDA/BLA), responses to health authority questions (HAQ/RTQ), and post-market updates and submissions; * Expand into global markets beyond the U.S. FDA, including Europe, Japan, and Latin America; and * Build advanced AI capabilities that will provide insights into therapeutic portfolios and empower strategic decision-making across the drug development process. Led by Brandon Rice, CEO and co-founder, Weave Bio provides an AI-native, cloud-based, software platform that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed.

FinanzNachrichten.de
Oct 16th, 2025
Weave Bio Secures $20M Series A Funding

Weave Bio has secured $20 million in Series A funding, led by USVP with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. This brings the company's total capital raised to $36 million. The funding will be used to enhance Weave's AI-native regulatory platform, expand global market reach, and build advanced AI capabilities. The platform aims to streamline regulatory workflows for pharmaceutical companies, biotech firms, and regulatory consultants.

Business Insider
Sep 30th, 2025
Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes

Parexel announces AI partnership with Weave Bio to accelerate regulatory submission processes.

INACTIVE